티움바이오
Financials
Valuation Metrics
티움바이오's Market Cap is ₩1081B. At end of 2025 it was ₩1799B. Ranked #1151 of 2,410 in KR market (top 48%), #605 of 1,631 on KOSDAQ (top 37%), #132 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 108.14B KRW | KR#1,151/2,410 Sec#132/231 |
| Revenue | 15.00B KRW | KR#2,209/2,410 Sec#165/231 |
| Net Income | -18.40B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 91.02B KRW | KR#1,853/2,410 Sec#148/231 |
| Net Assets | 32.52B KRW | KR#2,144/2,410 Sec#189/231 |
| Employees | 64 | KR#1,930/2,410 Sec#170/231 |
| Value | ||
| P/B | 3.33x | KR#2,175/2,410 Sec#180/231 |
| P/S | 7.21x | KR#2,240/2,410 Sec#159/231 |
| FCF Yield | -14.40% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -56.59% | KR#2,285/2,410 Sec#200/231 |
| ROA | -20.22% | KR#2,236/2,410 Sec#176/231 |
| Op. Margin | -107.28% | KR#2,295/2,410 Sec#176/231 |
| Revenue Growth | 104.49% | KR#80/2,410 Sec#16/231 |
| Financial Health | ||
| Debt Ratio | 179.90% | KR#2,031/2,410 Sec#213/231 |
| Total Debt | 27.26B KRW | KR#1,267/2,410 Sec#98/231 |
| FCF | -15.57B KRW | KR#1,824/2,410 Sec#170/231 |
| Cash | 3.69B KRW | KR#2,109/2,410 Sec#199/231 |
| Current Ratio | 0.93x | KR#1,799/2,410 Sec#176/231 |
| Performance | ||
| 1Y Return | -47.29% | KR#1,770/2,410 Sec#152/231 |
| 1M Return | -20.44% | KR#1,913/2,410 Sec#187/231 |
| From 52W High | -73.72% | KR#2,155/2,410 Sec#193/231 |
| 1Y MDD | -72.60% | KR#2,069/2,410 Sec#181/231 |
| Trading | ||
| Volume | 174,611 shares | KR#385/2,410 Sec#40/231 |
| Trading Value | 610.5M KRW | KR#707/2,410 Sec#74/231 |
| Foreign Own. | 3.43% | KR#1,166/2,410 Sec#106/231 |
| Per Share | ||
| EPS | -613 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,083 KRW | KR#2,286/2,410 Sec#208/231 |
Company Info
TiumBio, established in 2016 and headquartered in Seongnam-si, Gyeonggi-do, is a research and development company focused on rare/intractable disease treatments, specially listed on KOSDAQ in 2019. In 2024, it expanded its business by a small merger with natural cosmetics company Petraon, creating the Petraon Care Lab division, while its Protium Science unit offers biopharmaceutical process development services. The company develops immunocancer drugs and endometriosis treatments through its new drug creation system, generating revenue from technology transfer and product sales.